Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Trials in a Crunch

With the increasing budgetary challenges of running a drug development program, it's no wonder that one of the first places to feel the pinch is in programs for rare diseases. Clinical trials of therapeutics for these illnesses are having so much trouble finding cash that some companies are asking enrolled patients to help foot the bill, according to this article in the Wall Street Journal.


The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.